AU2013203450A1 - Transdermal delivery device and method - Google Patents
Transdermal delivery device and method Download PDFInfo
- Publication number
- AU2013203450A1 AU2013203450A1 AU2013203450A AU2013203450A AU2013203450A1 AU 2013203450 A1 AU2013203450 A1 AU 2013203450A1 AU 2013203450 A AU2013203450 A AU 2013203450A AU 2013203450 A AU2013203450 A AU 2013203450A AU 2013203450 A1 AU2013203450 A1 AU 2013203450A1
- Authority
- AU
- Australia
- Prior art keywords
- pad
- therapeutic compound
- skin
- backing layer
- person
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000037317 transdermal delivery Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 116
- 150000001875 compounds Chemical class 0.000 claims abstract description 112
- 238000007906 compression Methods 0.000 claims abstract description 28
- 230000006835 compression Effects 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 26
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 37
- 230000003444 anaesthetic effect Effects 0.000 claims description 23
- 239000000853 adhesive Substances 0.000 claims description 20
- 230000001070 adhesive effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 229960004194 lidocaine Drugs 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 13
- 238000000151 deposition Methods 0.000 claims description 12
- 239000004677 Nylon Substances 0.000 claims description 10
- 229920000297 Rayon Polymers 0.000 claims description 10
- 239000004744 fabric Substances 0.000 claims description 10
- 229920001778 nylon Polymers 0.000 claims description 10
- 239000002964 rayon Substances 0.000 claims description 10
- 229920000742 Cotton Polymers 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 229960002715 nicotine Drugs 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002984 plastic foam Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229940124326 anaesthetic agent Drugs 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229940125723 sedative agent Drugs 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 3
- 239000003204 tranquilizing agent Substances 0.000 claims description 3
- 230000002936 tranquilizing effect Effects 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229940022682 acetone Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 239000010410 layer Substances 0.000 description 64
- 210000003491 skin Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 11
- 206010002091 Anaesthesia Diseases 0.000 description 9
- 230000037005 anaesthesia Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 239000002344 surface layer Substances 0.000 description 9
- 229940019097 EMLA Drugs 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229940072358 xylocaine Drugs 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 6
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000001949 anaesthesia Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000005135 methemoglobinemia Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940060977 lidoderm Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A transdermal delivery device for delivering at least one active therapeutic compound to rapidly induce a therapeutic effect, the device comprising: a pad for receiving a depot 5 of the at least one therapeutic compound, the pad having a portion of material of high compression resistance; and the device also comprising a backing layer of greater cross section than the pad.
Description
1 TRANSDERMAL DELIVERY DEVICE AND METHOD Field of the Invention The present invention relates to a transdermal 5 delivery device and method for rapid transdermal delivery of active therapeutic compounds, in particular an anaesthetic compound. Background of the Invention 10 Skin is a structurally complex, relatively thick membrane that provides an effective barrier to the entry of substances into the body. To enter the body through the skin, substances must first be able to penetrate the stratum corneum, the outermost layer of the skin, which is generally 15 recognized as being primarily responsible for the skin's barrier properties. The stratum corneum is a thin layer of dense highly keratinised cells approximately 10 to 15 microns thick over most of the body, although thicker in areas such as the soles of the feet and the palms of the 20 hands. Due to the dense packing of these cells, the rate of diffusion of many compounds across the skin is relatively slow especially those substances applied in an ionized form. Once across the stratum corneum, substances must then cross the viable epidermis and diffuse into the papillary dermis 25 where they can enter the capillaries and be absorbed into the systemic circulation, enter lymphatic vessels or diffuse into the dermis and underlying tissue compartments. Therapeutic delivery devices and systems, including pads, patches and gels, are generally designed to 30 deliver one or more therapeutically active compounds into or through the skin at a predetermined rate over a specific period of time via the area on the skin where the system is applied. Such therapeutic devices and systems may be arranged to induce therapeutic action anywhere between the 35 surface of the skin and the systemic circulation. There are a large number of active compounds which can be applied in 2 this way and their differing chemical, physical and pharmacological characteristics have meant that there are a number of different transdermal delivery devices and systems which are commercially available. 5 Conventionally, transdermal patches or pads have at least one active compound reservoir, where the therapeutic compound is present in solid, liquid or dispersed molecular form, and an adhesion layer through which the patches or pads connect to the skin. In addition, 10 these patches or pads also usually have a protective backing cover, typically impermeable to the active compound. The patches or pads may also have a membrane in contact with the skin which is capable of regulating the release rate of the compound. 15 Common uses of such transdermal patches is for sustained release of a therapeutic substance over a long period of time at a generally constant rate. Examples of such patches include nicotine patches and testosterone patches. US 4784857 describes the structure of such a patch 20 in which the active agent is placed between the barrier layer and the release controlling layer. The pharmacological active agent is contained in a reservoir comprising a fibrous mat which is capable of absorbing and then releasing the active agent. The patch is designed to 25 be used in for example a 12 hour or 24 hour period and then discarded. One problem with many conventional transdermal patches is that they are relatively complicated and difficult to manufacture in particular due to the volatility 30 of the pharmacological active substances which consequently may evaporate during production of the patches. This increases the expense of the patches and limits their application to cost effective clinical applications. US RE 37934 E attempts to address this problem by providing a 35 higher concentration depot of the active substance in the reservoir matrix of the patch. US RE 37934 E describes a 3 nicotine patch in which a depot of 140g nicotine in 100g of an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylates is formed in the patch in 102 mg doses. After 24 hours, the nicotine released in vitro from 5 this patch was 56.54 mg per patch. International patent application no. PCT/US02/34077 describes a transdermal patch commercially available under the name Lidoderm® for treating non neuropathic pain which provides continuous transdermal 10 delivery of an anesthetic, specifically lidocaine, over extended periods of time to induce analgesia without causing anesthesia. Analgesia is the alleviation of pain whereas anesthesia refers to numbness, complete loss of sensation or paralysis. 15 Transdermal delivery of anesthetic substances is also provided to induce anesthesia of the nerve endings of the dermis. Application of the anesthetics in this way is typically provided prior to minor procedures such as needle insertion through the skin, biopsies, minor superficial 20 surgeries, the application of laser energy for cutaneous procedures such as the removal of hair and tattoos, for example. A commercially available product for providing transdermal delivery of an anesthetic to induce the 25 anaethesis is sold under the name EMLA@ which comprises a eutectic mixture of local anesthetics lidocaine and prilocaine. EMLA is available as a transdermal patch or as a gel. One significant problem with this product, however, is that it has a very long onset time, typically 45 to 90 30 minutes or even longer before the dermal anesthetic effect is present to a sufficient degree. Furthermore, deeper dermal anaethesis requires covering the application with an occlusive dressing to enhance penetration, which is inconvenient, messy and an added expense. 35 Another problem with using EMLA is that prilocaine is known to increase susceptibility to methemoglobinemia, 4 particularly in small children, which impairs the oxygen carrying capacity of haemoglobin. Lidocaine, whilst not susceptible to producing the same side effects, can cause systemic toxicity if used at overly high concentrations in 5 order to increase its transdermal permeability. US6299902 describes a composition to be used as a topical anesthetic with little or no prilocaine so as to avoid the risk of causing methemoglobinemia. The composition of US6299902 has two liquid phases; an aqueous phase and an oil phase, 10 wherein the oil phase has a relatively high concentration of a local anaesthetic agent, preferably lidocaine. Trials of this composition found no significant difference in the latency times between a cream of this composition and EMLA such that "following the application time of 60 minutes, the 15 6% lidocaine cream and EMLA cream produced comparable anaesthetic effects during the two hour period after removal of the creams". A number of other formulations have been reported as suitable compositions to be used in a transdermal 20 delivery device or system to reduce the onset time of anaesthesia compared to that of EMLA: - US2001/00014349 describes a composition comprising "at least one compound (1) modulating the reactivity nerve fibers, at least one compound (2) which is 25 water miscible, solubilises the compound (1) and is volatile, the weight ratio water/volatile compounds being greater than or equal to 0.8, the composition being devoid of any compound, other than water, which does not solubilise the compound (1) and is capable of retarding the evaporation 30 of the volatile compounds present in the composition and devoid of compound which solubilises the compound (1) and is non volatile". This composition was found to be efficacious at the end of only 30 minutes. - EP1293203 describes a composition comprising 35 lidocaine with the addition of a volatile carrier/penetration enhancer which is preferably a low 5 carbon alcohol. The minimum time for desensitisation using this composition was reported as 1 hour with the average desensitisation period being reported as 1.5 hours. - US2004/0131665 describes a topical anaesthetic 5 formulation comprising lidocaine, benzylalcohol and isopropyl alcohol which was found to generally produce an anaesthetic effect with 30 minutes. - US2004/0086556 describes a method of enhancing the flux of a local anaesthetic agent through a body surface 10 by administering a basic permeation enhancer to the localised region where a local anaesthetic agent has been administered, the enhancer comprising a pharmaceutically acceptable base and being present in an amount effective to produce a pH in the range of about 8.0 to 13.0. The 15 formulations described in US2004/0086556 were found to provide up to three fold more flux than in the absence of the basic permeation enhancer (NaOH). Thus, despite many attempts to improve the onset time of anaesthesia over that of EMLA, the onset time 20 remains undesirably long (generally 30 minutes or more). Furthermore, the use of permeation enhancers as described in some of the formulations above can cause undesirable irritation of the skin. 25 Summary of the Invention According to a first aspect of the present invention there is provided a transdermal delivery device for delivering at least one active therapeutic compound to rapidly induce a therapeutic effect, the device comprising: 30 a pad for receiving a depot of the at least one therapeutic compound, the pad having a portion of material of high compression resistance; and the device also comprising a backing layer of greater cross-section than the pad. 35 The device may also comprise an amount of the at least one therapeutic compound deposited within the pad.
6 The amount of the at least one therapeutic compound may be absorbed within the pad. The pad and the backing layer may be fixed together. 5 In another arrangement, the pad and backing layer may be readily separable from another. The pad may be of any desirable cross-sectional shape such as a square, circle or rectangle. The pad is generally resistant to compression in a 10 direction through the thickness of the pad such that under compression it does not significantly reduce in thickness. The pad may be not so resistant to lateral compression of the pad. The pad may have a thickness of 0.5 - 10mm. 15 The pad may comprise a plurality of layers of material. Each layer may have a different composition. The portion of material of high compression resistance may be one layer of the pad. The material of high compression resistance may be 20 a cotton material, preferably a compressed cotton material, preferably an unwoven material. The cotton material may or may not be blended with other fibres such as rayon and synthetic fibres including polyester and nylon for example. 25 The pad may comprise a layer of plastic foam. The plastic foam may be polyethelene foam. The pad may comprise a surface layer formed for example of perforated polyethelene film, nylon net, rayon net or cellulose unwoven cloth for example. 30 The surface layer may be formed on one face of the pad. The surface layer may be formed on both faces of the pad. The surface layer may be formed on the side or 35 sides of the pad. The pad may comprise an outer shell and an inner 7 core. The outer shell may be firmer and denser than the inner core. The outer shell may be formed from perforated 5 polyethylene film, nylon net, rayon net or cellulose unwoven cloth. The inner core may include the foam layer and the high compression resistant layer. The pad may be capable of being compressed 0.1-75% 10 of its preloaded thickness. The pad may have an adsorptivity of 0.001-l0mL/cm 3 preferably 0.001 to 1.1 mL/cm 3 . The pad may be hydrophilic,or lipophilic or may be a combination of hydrophilic and lipophilic to varying 15 degrees. The backing layer may be non-elastic or elastic. The backing layer may have an adhesive surface for adhering to the person's skin. The backing layer may be impermeable to the at 20 least one active therapeutic compound. The transdermal delivery device may also comprise an aperture in the backing layer through which an amount of the at least one therapeutic compound may be deposited in the pad. 25 The transdermal delivery device may also comprise a covering layer for covering the adhesive surface of the backing layer prior to use of the device. The covering layer is generally removable from contact with the adhesive surface of the backing layer to 30 enable use of the device. At least one therapeutic compound may be in solid or liquid form. At least one therapeutic compound may be a powder. At least one therapeutic compound may be in pure 35 form. At least one therapeutic compound may be in an 8 unionized form. "Unionized form" is understood to mean that a substantial portion of the therapeutic compound carries no overall charge, either in solution or not. The at least one therapeutic compound, where in 5 liquid form, may be a solute in a solvent. The depot may comprise a solution of the at least one therapeutic compound and a solvent. The at least one therapeutic compound may be at a saturation or near saturation concentration in the solvent. 10 The at least one therapeutic compound may comprise any one or combination of anaesthetics, corticosteroids, non-steroidal anti-inflammatory agents, analgesics, antifungal agents, nicotine, vasodilators, vasoconstrictors, hypnotically active sedatives, tranquilizers, 15 antihypersensitive agents, diuretics, antibiotics, vitamins, antiepileptic agents, antihistamines, hormones, chemotherapeutic and cytotoxic agents and any other compounds which can be delivered transdermally. The solvent may comprise any one or combination of 20 water, alcohols, propylene glycol, isopropylmyristate, liquid paraffin, glycerin, acetone, oleic acid, olive oil, essential oils or any other hydrophilic or lipophilic vehicle in which the therapeutic compound(solute) is able to be maintained preferably in an unionized form. 25 Preferably, the at least one therapeutic compound is any one or more anaesthetic compound. The anaesthetic compound may be an amine, preferably lidocaine. The anaesthetic compound may be any other agent capable of achieving sufficient anaesthesia via 30 passive skin penetration. Preferably, the solvent is water. The lidocaine may have a solubilised concentration in water of 0.001-2%, preferably 0.01-2%, preferably 0.1-2%, preferably 1-2%, preferably 1.5-2.0%, more preferably 35 approximately 2% by weight. The lidocaine may be at a saturated or near 9 saturated concentration in the solvent. The transdermal delivery device may also comprise a dye deposited within the pad for indicating the position that the device is placed on the person's skin. 5 According to a second aspect of the present invention, there is provided a transdermal delivery device for delivering at least one therapeutic compound to rapidly induce a therapeutic effect, the device comprising: a pad having a portion of material of high 10 compression resistance; a backing layer of greater cross-section than the pad; and an aperture in the backing layer through which an amount of the at least one therapeutic compound may be 15 deposited in the pad. According to a third aspect of the present invention, there is provided a method for rapidly inducing a therapeutic effect comprising: providing a transdermal delivery device comprising 20 a pad having a portion of material of high compression resistance and a backing layer of greater cross-section than the pad; depositing in the pad an amount of at least one therapeutic compound; and 25 applying the pad to a person's skin to enable the at least one therapeutic compound to rapidly induce the therapeutic effect. The at least one therapeutic compound may be deposited in the pad during forming of the transdermal 30 delivery device. The step of depositing may comprise depositing the at least one therapeutic compound in the pad through an aperture in the backing layer. The step of depositing may comprise contacting the 35 pad with the at least one therapeutic compound. Contacting the pad with the at least one 10 therapeutic compound may comprise pouring, coating, dipping, swabbing, brushing, or any other suitable contacting step. The step of depositing may result in the at least one therapeutic compound being absorbed in the pad. 5 According to a fourth aspect of the present invention, there is provided a method for rapidly inducing a therapeutic effect comprising: providing a transdermal delivery device comprising a pad having a portion of material of high compression 10 resistance, a backing layer of greater cross-section than the pad, and an amount of at least one therapeutic compound deposited within the pad; and applying the pad to a person's skin to enable the at least one therapeutic compound to rapidly induce the 15 therapeutic effect. The transdermal delivery device may comprise a device according to the first or second aspect of the present invention. The therapeutic effect may be sufficiently induced 20 within 15 minutes of application of the pad to the person's skin, preferably within 10 minutes. The therapeutic effect may be substantially lost within 40 minutes of removal of the pad from the person's skin, preferably within 30 minutes. 25 The at least one therapeutic compound may be an anaesthetic compound, preferably lidocaine, and the therapeutic effect may be anaethesia. The step of applying the pad to the person's skin may comprise applying substantial pressure to the pad 30 towards the person's skin. The step of applying the pad to the person's skin may comprise fixing the pad to the person's skin. Fixing the pad to the person's skin may comprise adhering the backing layer to the person's skin, preferably 35 by placing an adhesive surface of the backing layer on the person's skin.
11 In other arrangement, fixing the pad to the person's skin may comprise wrapping the backing layer around a portion of the person. In this embodiment, the backing layer may be in the form of a bandage or other suitable 5 strip of cloth. The step of applying the pad to the person's skin may comprise stretching the backing layer of the transdermal delivery device. According to a fifth aspect of the present 10 invention, there is provided a transdermal delivery kit for delivering at least one therapeutic compound to rapidly induce a therapeutic effect, the kit comprising: a transdermal delivery device according to the first or second aspect of the present invention; and 15 an applicator for depositing the at least one therapeutic compound in the pad. The applicator may be used to deposit the at least one therapeutic compound in the pad through the aperture of the backing layer. 20 The applicator may comprise a syringe. The kit may comprise an amount of the at least one therapeutic compound, preferably stored within the applicator prior to use of the kit. According to a sixth aspect of the present 25 invention, there is provided a transdermal delivery device for delivering at least one active therapeutic compound to rapidly induce a therapeutic effect, the device comprising: a pad for receiving a depot of the at least one therapeutic compound, the pad comprising an outer shell and 30 an inner core, the outer shell being firmer and denser than the inner core. The device may also comprise a backing layer of greater cross-section than the pad. The outer shell may be formed from a perforated 35 polyethelene film, nylon net, rayon net or cellulose unwoven cloth.
12 The inner core may comprise a plurality of layers. The inner core may comprise a layer of plastic foam. The plastic foam may be polyethelene foam. 5 The inner core may comprise a layer of compressed cotton material. The outer shell may comprise a surface layer formed on one face of the pad. The outer shell may comprise surface layers formed 10 on both faces of the pad. The outer shell may comprise a surface layer formed on the side or sides of the pad. Brief Description of the Drawings 15 Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which: Figure 1 is cross-sectional schematic view of a transdermal delivery device according to an embodiment of 20 the present invention; Figures 2A and B are exploded views of a pad of the transdermal delivery device according to embodiments of the present invention; Figure 3 is cross-sectional schematic view of a 25 transdermal delivery device according to another embodiment of the present invention; and Figure 4 is cross-sectional schematic view of a transdermal delivery device according to a further embodiment of the present invention. 30 Detailed Description of Embodiments Referring firstly to Figures 1 and 3, there is shown a transdermal delivery device 10 for delivering at least one active therapeutic compound to rapidly induce a 35 therapeutic effect. The device 10 comprises a pad 11 for receiving a depot of the at least one therapeutic compound.
13 The pad 11 has a portion of material of high compression resistance. The device 10 also has a backing layer 12 of greater cross-section than the pad 11. The pad 11 is applied to a person's skin 13 to enable transdermal delivery of the 5 at least one therapeutic compound. In the embodiment shown in Figure 1, the pad 11 and the backing layer 12 are fixed together. Whereas, in the embodiment shown in Figure 3, the pad and backing layer are readily separable from another. The pad 11 or at least the portion of the pad of 10 high compression resistance, is generally resistant to compression in a direction through the thickness of the pad 11 such that under compression it does not significantly reduce in thickness, but may be not so resistant to lateral compression. As such, the pad 11 may be commonly referred to 15 as a "pressure pad". Pressure pads have been conventionally used for aiding in the haemostasis of punctures (ie. blood clotting) by the application of pressure. In addition to having the aforementioned property of not significantly reducing in thickness when under compression, pressure pads 20 are strongly adsorbent of fluids so as to prevent the flow of blood away from the punctures. Surprisingly, it has been found by the inventor of the present invention that such pads may be used in the transdermal delivery device 10 of the present invention. 25 The pad 11 may be hydrophilic, lipophilic or maybe a combination of hydrophilic and lipophilic, in order to enhance its ability to absorb fluids. The pad 11 comprises a plurality of layers of material and each layer may have a different composition. 30 The portion of material of high compression resistance typically is one layer of the pad 11. This layer is formed from a compressed unwoven cotton cloth which may or may not be blended with other fibres such as rayon or synthetic fibres including nylon and polyester. The pad 11 may also 35 comprise a "cushioning" layer of polyethelene foam for example. The pad may further comprise a surface layer formed 14 for example from perforated polyethelene film, nylon net, rayon net, or cellulose unwoven cloth. Referring to Figures 2A and 2B, in one embodiment, the pad 11 comprises an outer shell 20 and an inner core 21. 5 The outer shell 20 is firmer and denser than the inner core 21. The outer shell 20, as shown in Figures 2A and 2B, generally comprises surface layers formed on the faces of the pad and also around the side of the pad. The outer shell 20 is formed preferably from perforated polyethelene film, 10 but may be formed from nylon net, rayon net or cellulose unwoven cloth. The inner core 21 may include the polyethelene foam layer as well as the compressed unwoven cotton cloth layer. Without wishing to be bound by theory, it is understood that the firmer and denser outer shell 20 15 reduces undesirable seepage of liquid from the pad 11 under the application of pressure, particularly out of the sides of the pad. The outer shell 20 is also understood to enhance the compression resistance of the pad 11. The pad 11 is formed such that it generally has 20 the following properties: - a thickness of 0.5 - 10mm. - an adsorptivity of 0.001-10ml/cm 3 , preferably 0.001 1.1mL/cm 3 - is capable of being compressed to 0.1-75% of its preloaded 25 thickness. The pad 11 may be of any desirable cross-sectional shape such as a square, circle, oval or rectangle. The backing layer 12 is elastic, which enables it to be stretched as the transdermal delivery device 10 is applied 30 to a person's skin. This substantially increases the pressure applied to the pad 11 towards the person's skin. The backing layer 12 has an adhesive surface 14 for adhering to the person's skin and which also holds the backing layer 12 in its stretched position. The backing layer 12 is also 35 impermeable to the at least one active therapeutic compound so as to avoid any undesirable leaking of the therapeutic 15 compound through the backing layer 12. Although not shown in the Figures, the transdermal delivery device 10 may also comprise a covering layer for covering the adhesive surface 14 of the backing layer 12 prior to use of the device 10. 5 The covering layer is removable from contact with the adhesive surface 14 of the backing layer 12 to enable use of the device 10. The transdermal delivery device 10 may also have a dye deposited within the pad for indicating the position 10 that the device 10 is placed on the person's skin. The at least one therapeutic compound may be deposited in the pad 11 during forming of the transdermal delivery device 10. However, in other embodiments this is not the case and the at least one therapeutic compound is deposited in the 15 pad by contacting the pad 11 with the at least one therapeutic compound. Contacting the pad 11 with the at least one therapeutic compound may involve pouring, coating, dipping, swabbing, brushing, or any other suitable contacting step. As a result of contacting the pad 11 with 20 the at least one therapeutic compound, where the at least one therapeutic compound is provided in a liquid, it is generally absorbed in the pad 11. Referring to the embodiment of the device 10 shown in Figure 4, the device 10 also comprises an aperture 15 in 25 the backing layer 12 through which an amount of the at least one therapeutic compound may be deposited in the pad 11. In this way the at least one compound may be deposited in the pad 11 even after the pad 11 has been applied to the person's skin. 30 The depot received in the pad 11 generally comprises a solution of the at least one therapeutic compound and a solvent. Although, in other embodiments, the at least one therapeutic compound may be provided in solid or liquid form. Where provided in a solution, the at least 35 one therapeutic compound is preferably in an unionized form at a saturation or near saturation concentration in the 16 solvent. The at least one therapeutic compound may comprise any one or combination of anaesthetics, corticosteroids, non-steroidal anti-inflammatory agents, analgesics, 5 antifungal agents, nicotine, vasodilators, vasoconstrictors, hypnotically active sedatives, tranquilizers, antihypersensitive agents, diuretics, antibiotics, vitamins, antiepileptic agents, antihistamines, hormones, chemotherapeutic and cytotoxic agents and any other 10 compounds which can be delivered transdermally. The solvent may comprise any one or combination of water, alcohols, propylene glycol, isopropylmyristate, liquid paraffin, glycerin, acetone, oleic acid, olive oil, essential oils or any other hydrophilic or lipophilic 15 vehicle in which the therapeutic compund(s) (solute)is able to be maintained preferably in an unionized form. However, in a particular embodiment of the present invention, the at least one therapeutic compound is any one or more anaesthetic compound, preferably an amine, more 20 preferably lidocaine typically at a concentration in a solvent of water of 0.001-4%, preferably approximately 2% by weight (where the lidocaine is at or near a saturated concentration). Where alternative solutions to water are employed the therapeutic compound will need to be adjusted 25 to achieve saturation or near saturation solubility of the therapeutic compound. Using the transdermal delivery device 10 it has been found that the therapeutic effect (anaethesia) of the lidocaine is sufficiently induced within 15 minutes of application of the pad 11 to the person's 30 skin, preferably within 10 minutes. Furthermore, it has been found that the anaesthetic effect of the lidocaine is substantially lost within 40 minutes of removal of the pad 11 to the person's skin, preferably within 30 minutes. Advantageously, this minimizes unnecessarily prolonged 35 anesthesia of the skin. Notably, the device 10 may also be provided as 17 part of a kit which also comprises an applicator, such as a syringe, for depositing the at least one therapeutic compound in the pad 11. An amount of the at least one therapeutic compound may be stored within the applicator 5 prior to use of the kit. EXAMPLES Example 1 10 A transdermal delivery device was produced comprising an adhesive backing layer (3.5 cm diameter circle of non-elastic tape) and a central high compression resistant pad (1.5 cm diameter circle of a fibrous matrix of a sterile cotton band material) attached to the centre of 15 the circular backing membrane, 3 mm thickness (uncompressed)). The central pad was loaded with one of the following solutions: 1. 500 pL of a saturated solution of the local anaesthetic 20 lidocaine base (unionized form, approx 2% concentration) in distilled water 2. 500 pL of a 2% lidocaine hydrochloride solution in saline (Xylocaine injection solution). 25 The device was applied to separate treatment sites for each of the above solutions on the forearm of two female volunteers and the device left in contact with the skin for 10 minutes. After 10 minutes the devices were removed, the 30 surface of the skin blotted with tissue and a 25g 5/8" injection needle inserted vertically into the application area on the skin of each site and the depth of penetration of the needle determined at the point when pain was perceived. 35 In volunteer 1, the needle was able to be inserted to a depth of 5 mm before dermal irritation was perceived 18 following the application of delivery system containing the lidocaine base in water as outlined in 1 above. Insertion of the needle into the site treated with the delivery system containing the active substance depot outlined in 2 above 5 resulted in immediate needle prick pain and no insertion was performed. In volunteer 2, the needle was also able to be inserted into the dermis before irritation was perceived following the application of delivery system containing the 10 lidocaine base in water as outlined in 1 above. Insertion of the needle into the site treated with the delivery system containing the active substance depot outlined in 2 above again resulted in immediate needle prick pain and no insertion was performed. 15 These results indicate the achievement of dermal anaesthesia following the short 10 minute application period of the delivery device. Example 2 20 A pad having a diameter of 1.6cm had 500pL of 2% lidocaine base (unionized) solution in distilled water deposited therein. The pad was subsequently placed on the inner left forearm of a human volunteer and adhered to skin using a backing layer of surgical tape (3MM Micropore 25 Surgical Tape). After 15 minutes of application, the pad was removed. A 25g 5/8" injection needle was used to prick test the site to around 1mm depth over two 10 minute intervals; at 10, 20 and 30 minutes after application of the pad. A control site approximately 6cm from the anaethetised site 30 was also tested. The prick testing found that: after 10 minutes, the area of the skin 1cm from the pad perimeter was anaesthetized in addition to the area underlying the pad 35 after 20 minutes, the area of the skin 2.5cm from the pad was anaesthetized 19 after 30 minutes, the anaesthetic effect was lost. Example 3 A transdermal delivery device is produced comprising a 5 central high compression resistant pad (produced by Nichiban Pty Ltd) and an adhesive backing layer of Opsite cut into a circle of approximately double the diameter of the pad. The device was used in the following trials: 10 Trial A The pad was placed on the adhesive side of the adhesive backing layer and loaded with 0.5ml of a saturated solution of the local anesthetic lidocaine base (unionised form, approximately 2% concentration) in distilled water. The 15 device was subsequently applied on a volunteers left deltoid region for ten minutes. A 25g 5/8" needle was subsequently inserted in 1mm increments to a depth of 25mm (which was the full length of the shaft of the needle). The volunteer did not feel any pain. 20 Trial B The pad was placed on the adhesive side of the adhesive backing layer and loaded with 0.5ml of a 2% saturated solution of lidocaine base in distilled water. The device 25 was subsequently applied to a volunteers left deltoid region for 10 minutes and 2ml of a 1% lidocaine hydrochloride solution in saline (standard Xylocaine injection solution) was infiltrated intradermally on the site where the pad had been applied. No pain was felt by the volunteer during the 30 infiltration of the Xylocaine solution. On a pain scale from 1-10, the volunteer rated it as a 1. Trial C The pad was placed on the adhesive side of the adhesive 35 backing layer and was loaded with 0.5ml of a 2% lidocaine hydrochloride solution in saline. The device was 20 subsequently applied to a volunteers right deltoid region for 15 minutes. A 25g 5/8" needle was injected in 1mm increments at the site to a depth of approximately 15mm before marginal pain was felt by the volunteer. 5 Trial D The pad was placed on the adhesive side of the adhesive backing layer and loaded with 0.5ml of a 2% lidocaine hydrochloride solution in saline. The device was 10 subsequently applied to a volunteers right deltoid region for 15 minutes. 2ml of a 1% lidocaine hydrochloride solution in saline (Xylocaine) was infiltrated intradermally on the site where the pad had been applied. Marginal pain was felt by the volunteer who rated the infiltration of Xylocaine on 15 a pain scale from 1-10 as 3-4. Trials B and D above compare favourably to the conventional technique for inducing local dermal anesthesia in which 2ml of Xylocaine (1% lidocaine hydrochloride solution in saline) 20 is injected into a site. Such conventional techniques cause immediate pain upon injection of a needle and subsequently on commencement of infiltration of the Xylocaine solution. In the claims which follow and in the preceding 25 description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not 30 to preclude the presence or addition of further features in various embodiments of the invention. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of 35 the common general knowledge in the art, in Australia or any other country.
21 Variations and modifications can be made in respect of the invention described above and defined in the following statements of claim.
Claims (52)
1. A transdermal delivery device for delivering at least one active therapeutic compound to 5 rapidly induce a therapeutic effect, the device comprising: a pad for receiving a depot of the at least one therapeutic compound, the pad having a portion of material of high compression 10 resistance; and the device also comprising a backing layer of greater cross-section than the pad.
2. The device according to claim 1 further comprising 15 an amount of the at least one therapeutic compound deposited within the pad.
3. The device according to any one of the preceding claims wherein the pad and the backing layer 20 are fixed together.
4. The device according to claims 1 or 2 wherein the pad and backing layer are readily separable from one another. 25
5. The device according to any one of the preceding claims wherein the pad has a thickness of 0.5 - 10mm. 30
6. The device according to any one of the preceding claims wherein the pad comprises a plurality of layers of material.
7. The device according to claim 6 wherein each layer 35 of the pad has a different composition. 23
8. The device according to claim 6 or claim 7 wherein the portion of material of high compression resistance is one layer of the pad. 5
9. The device according to any one of the preceding claims wherein the material of high compression resistance is a cotton material.
10. The device according to claim 9 wherein the cotton 10 material is blended with fibres selected from rayon, polyester or nylon, or mixtures of two or more of these fibres.
11. The device according to any one of claims 6 to 10 15 wherein the pad comprises a layer of plastic foam.
12. The device according to any one of the preceding claims wherein the pad comprises a surface 20 layer formed of perforated polyethelene film, nylon net, rayon net or cellulose unwoven cloth.
13. The device according to any one of the preceding 25 claims wherein the pad comprises an outer shell and an inner core and wherein the outer shell is firmer and denser than the inner core. 30
14. The device according to claim 13 wherein the outer shell is formed from perforated polyethylene film, nylon net, rayon net or cellulose unwoven cloth and the inner core includes a foam layer and a high compression resistant 35 layer. 24
15. The device according to any one of the preceding claims wherein the pad is capable of being compressed 0.1-75% of its preloaded thickness. 5
16. The device according to any one of the preceding claims wherein the pad has an adsorptivity of 0.001-1OmL/cm 3 . 10
17. The device according to any one of the preceding claims wherein the pad is hydrophilic, or lipophilic or a combination of hydrophilic and lipophilic. 15
18. The device according to any one of the preceding claims wherein the backing layer has an adhesive surface for adhering to the person's skin. 20
19. The device according any one of the preceding claims wherein the backing layer is impermeable to the at least one active therapeutic compound. 25
20. The device according any one of the preceding claims wherein the device further comprises an aperture in the backing layer through which an amount of the at least one therapeutic compound may be deposited in the 30 pad.
21. The device according to any one of the preceding claims wherein the device further comprises a covering layer for covering the adhesive 35 surface of the backing layer prior to use of the device and is removable from contact 25 with the adhesive surface of the backing layer to enable use of the device.
22. The device according to any one of the preceding 5 claims wherein the at least one therapeutic compound is in an unionized form.
23. The device according to any one of the preceding claims wherein the depot comprises a 10 solution of the at least one therapeutic compound and a solvent.
24. The device according claim 23 wherein the at least one therapeutic compound is at a saturation 15 or near saturation concentration in the solvent.
25. The device according to either claims 23 or 24 wherein the solvent comprises any one or 20 combination of water, alcohols, propylene glycol, isopropylmyristate, liquid paraffin, glycerine, acetone, olecic acid, olive oil or essential oils. 25 26. The device according to any one of the preceding claims wherein the at least one therapeutic compound comprises any one or combination of anaesthetics, corticosteroids, non-steroidal anti-inflammatory agents, analgesics, 30 antifungal agents, nicotine, vasodilators, vasoconstrictors, hypnotically active sedatives, tranquilizers, antihypersensitive agents, diuretics, antibiotics, vitamins, antiepileptic agents, antihistamines, 35 hormones, chemotherapeutic and cytotoxic agents.
26
27. The device according to any one of the preceding claims wherein the at least one therapeutic compound is any one or more anaesthetic 5 compound.
28. The device according to claim 27 wherein the anaesthetic compound is an amine. 10
29. The device according to claim 28 wherein the amine is lidocaine.
30. The device according to claim 29 wherein the lidocaine has a concentration in water of 15 0.001-4%.
31. The device according to claim 29 wherein the lidocaine has a concentration of approximately 2% by weight. 20
32. The device according to any one of the preceding claims further comprising a dye deposited within the pad for indicating the position that the device is placed on the person's 25 skin.
33. A transdermal delivery device for delivering at least one therapeutic compound to rapidly induce a therapeutic effect, the device 30 comprising: a pad having a portion of material of high compression resistance; a backing layer of greater cross-section than the pad; and 35 an aperture in the backing layer through which an amount of the at least one therapeutic 27 compound may be deposited in the pad.
34. A transdermal delivery device for delivering at least one active therapeutic compound to 5 rapidly induce a therapeutic effect, the device comprising: a pad for receiving a depot of the at least one therapeutic compound, the pad comprising an outer shell and an inner core, the outer 10 shell being firmer and denser than the inner core.
35. A method for rapidly inducing a therapeutic effect comprising: 15 providing a transdermal delivery device comprising a pad having a portion of material of high compression resistance and a backing layer of greater cross-section than the pad; depositing in the pad an amount of at least one 20 therapeutic compound; and applying the pad to a person's skin to enable the at least one therapeutic compound to rapidly induce the therapeutic effect. 25
36. A method according to claim 35 wherein the at least one therapeutic compound is deposited in the pad during forming of the transdermal delivery device. 30
37. The method according to claim 35 wherein the step of depositing comprises depositing the at least one therapeutic compound in the pad through an aperture in the backing layer. 35
38. The method according to claim 35 wherein the step of depositing comprises contacting the pad 28 with the at least one therapeutic compound.
39. A method for rapidly inducing a therapeutic effect comprising: 5 providing a transdermal delivery device comprising a pad having a portion of material of high compression resistance, a backing layer of greater cross-section than the pad, and an amount of at least one therapeutic compound 10 deposited within the pad; and applying the pad to a person's skin to enable the at least one therapeutic compound to rapidly induce the therapeutic effect. 15
40. The method according to claim 39 wherein the transdermal delivery device comprises a device according to any one of claims 1 to 34. 20
41. The method according to claim 39 or claim 40 wherein the therapeutic effect is sufficiently induced within 15 minutes of application of the pad to the person's skin. 25
42. The method according to any one of claims 39 to 41 wherein the therapeutic effect is substantially lost within 40 minutes of removal of the pad from the person's skin. 30
43. The method according to any one of claims 39 to 42 wherein the at least one therapeutic compound is an anaesthetic compound and the therapeutic effect is anaethesia. 35
44. The method according to any one of claims 39 to 43 29 wherein the step of applying the pad to the person's skin comprises applying substantial pressure to the pad towards the person's skin. 5
45. The method according to any one of claims 39 to 44 wherein the step of applying the pad to the person's skin comprises fixing the pad to the person's skin. 10
46. The method according to claim 45 wherein fixing the pad to the person's skin comprises adhering the backing layer to the person's skin. 15
47. The method according to claim 45 wherein fixing the pad to the person's skin comprises wrapping the backing layer around a portion of the person. 20
48. The method according to any one of claims 39 to 47 wherein the step of applying the pad to the person's skin comprises stretching the backing layer of the transdermal delivery 25 device.
49. A transdermal delivery kit for delivering at least one therapeutic compound to rapidly induce a therapeutic effect, the kit comprising: 30 a transdermal delivery device as claimed in any one of claims 1 to 34; and an applicator for depositing the at least one therapeutic compound in the pad. 35
50. The kit according to claim 49 wherein the applicator comprises a syringe. 30
51. The kit according to any one of claims 49 or 50 wherein the kit comprises an amount of the at least one therapeutic compound. 5
52. The kit according to claim 51 wherein the at least one therapeutic compound is stored within the applicator prior to use of the kit.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013203450A AU2013203450A1 (en) | 2008-09-26 | 2013-04-10 | Transdermal delivery device and method |
| AU2015200513A AU2015200513A1 (en) | 2008-09-26 | 2015-02-03 | Transdermal delivery device and method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008905029 | 2008-09-26 | ||
| AU2009295338A AU2009295338B2 (en) | 2008-09-26 | 2009-09-21 | Transdermal delivery device and method |
| AU2013203450A AU2013203450A1 (en) | 2008-09-26 | 2013-04-10 | Transdermal delivery device and method |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009295338A Division AU2009295338B2 (en) | 2008-09-26 | 2009-09-21 | Transdermal delivery device and method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015200513A Division AU2015200513A1 (en) | 2008-09-26 | 2015-02-03 | Transdermal delivery device and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013203450A1 true AU2013203450A1 (en) | 2013-05-02 |
Family
ID=48482627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013203450A Abandoned AU2013203450A1 (en) | 2008-09-26 | 2013-04-10 | Transdermal delivery device and method |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2013203450A1 (en) |
-
2013
- 2013-04-10 AU AU2013203450A patent/AU2013203450A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009295338B2 (en) | Transdermal delivery device and method | |
| Ramadon et al. | Enhancement strategies for transdermal drug delivery systems: Current trends and applications | |
| JP2701951B2 (en) | Printed skin permeable drug delivery device | |
| KR100764156B1 (en) | Intradermal Penetrants for Local Administration of Local Anesthetics | |
| US20080008745A1 (en) | Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles | |
| JP2006143750A (en) | Improved transdermal device having decreased delamination | |
| WO2001026705A2 (en) | A dual adhesive transdermal drug delivery system | |
| KR20020063168A (en) | Local prevention or amelioration of pain from surgically closed wounds | |
| JPH11505843A (en) | Skin permeation enhancer compositions using acyl lactylate compounds | |
| JPH11512073A (en) | Skin permeation enhancer composition containing glycerol monolaurate and lauryl acetate | |
| AU2001245449A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| EP2637647A2 (en) | Sheet and liquid combination systems for dermal drug delivery | |
| CN105431175A (en) | Transdermal delivery system | |
| Pawar et al. | Recent advancements in transdermal drug delivery system | |
| ES2670707T3 (en) | Composition to improve transdermal absorption of a drug and prepared in patch | |
| US20030054017A1 (en) | Alcohol based topical anesthetic formulation and method | |
| JP3002772B2 (en) | Patch and its manufacturing method | |
| AU2013203450A1 (en) | Transdermal delivery device and method | |
| AU2015200513A1 (en) | Transdermal delivery device and method | |
| RU2434631C2 (en) | Transdermal therapeutic system for volatile and/or thermolabile substances | |
| US20250134838A1 (en) | Dermal waxing patch | |
| US10245272B2 (en) | Transmembrane penetration enhancer | |
| US20250375397A1 (en) | Topical Patch Device | |
| Rahman et al. | A Review on Trasdermal Patch and Marketed Preparations | |
| JP2006515617A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |